Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer

Resectable Esophageal Cancer Clinical Trial

Official title:
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer

Status Completed

Clinical Trial Summary

Despite the availability of several preoperative diagnostic techniques, accurate pretreatment staging of esophageal cancer (EC) remains challenging. Therefore, The investigators evaluated the prognostic significance of circulating tumor cells (CTCs) in patients with EC.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01858805
Study type	Observational
Source	Universitätsklinikum Hamburg-Eppendorf
Contact
Status	Completed
Phase	N/A
Start date	April 2010
Completion date	April 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03490292` - Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer	Phase 1/Phase 2
Terminated	`NCT00827671` - Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma	Phase 2
Recruiting	`NCT04006041` - Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer	Phase 2
Recruiting	`NCT05307835` - Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection	Phase 1